United Kingdom based Heart Failure Clinical Trials & Research Studies Near You (Updated 8/25)

The DAPA-MEMRI Trial

NCT04591639

Recruiting

Diabetes mellitus is among the top 10 causes of death worldwide with an increasing incidence. Patients with diabetes are at risk of developing heart failure which is characterised by significant changes in the heart muscle including scarring and thickening. Contraction of the heart involves movement of calcium across the heart muscle and disruption of this process is an early change seen in heart failure. Recently, a drug therapy (SGLT2 inhibitor therapy) in patients with diabetes was shown to b... Read More

Diabetes mellitus is among the top 10 causes of death worldwide with an increasing incidence. Patients with diabetes are at risk of developing heart failure which is characterised by significant changes in the heart muscle including scarring and thickening. Contraction of the heart involves movement of calcium across the heart muscle and disruption of this process is an early change seen in heart failure. Recently, a drug therapy (SGLT2 inhibitor therapy) in patients with diabetes was shown to benefit patients with heart failure but the mechanisms of benefit are unknown. Our hypothesis is that calcium handling is altered in patients with either type 2 diabetes mellitus (T2DM) or heart failure and that SGLT2 inhibitors can improve this in heart failure irrespective of the presence of T2DM. Scanning the heart using magnetic resonance imaging (MRI) enables detailed assessment of its structure and function by using a new contrast 'dye' containing manganese that has shown advantages over traditional contrast. We plan to further test this new dye as it has the potential to track and quantify improvements in heart function over time and detect changes in calcium handling in the heart muscle, making it an ideal measure to identify the mechanisms of benefit from SGLT2 inhibitor therapy. The study population will comprise patients with heart failure with and without type 2 diabetes, patients with type 2 diabetes without heart failure and healthy volunteers. Baseline comparisons will be made between the four groups before progressing to the randomised controlled trial with heart failure patients only. Patients will have a clinical assessment and blood tests, electrocardiogram, echocardiogram and MRI of the heart at each visit. If successful, this study will give us significant insights into mechanisms of action of SGLT2 inhibitors in heart failure and will enable us to tailor specific treatments in heart failure patients. Read Less

Gender:

ALL

Ages:

18 years and above

Trial Updated:

06/23/2025

Locations: University of Edinburgh, Edinburgh, Scotland

Conditions: Heart Failure, Diabetic Cardiomyopathies

Register for Updates

Learn More ›

Stereotactic Ablative Radiotherapy for the Treatment of Refractory Ventricular Tachycardia

NCT05696522

Recruiting

Ventricular tachycardia (VT) is an abnormal rhythm arising from the bottom chambers (ventricles) of the heart. The hearts of most patients who develop VT have been previously damaged by a myocardial infarction (heart attack) or other heart muscle diseases (cardiomyopathies). The damage produces scar or fatty deposits that conduct electrical impulses slowly allowing VT to occur. Recurrent episodes of VT can compromise heart function and increase mortality. VT is prevented by special drugs but th... Read More

Gender:

ALL

Ages:

Between 18 years and 85 years

Trial Updated:

06/18/2025

Locations: St Bartholomew's Hospital, London, Not set

Conditions: Radiotherapy; Complications, Ventricular Tachycardia, Structural Heart Abnormality, Heart Failure

Register for Updates

Learn More ›

pErsonalised Nocebo Assessment of Beta-blockEr Symptoms in Heart Failure

NCT07029906

Recruiting

Beta-blocker tablets are an effective treatment for heart failure that make people live longer and reduce the need to be admitted to hospital. Many patients who are at high risk of death are prescribed beta-blockers, but later choose to stop taking them because of symptoms that they perceive to be side-effects. Some patients' symptoms may genuinely be side-effects due to the beta-blocker tablets, but, in reality, many of the symptoms which may lead to people stopping beta-blockers are actually e... Read More

Beta-blocker tablets are an effective treatment for heart failure that make people live longer and reduce the need to be admitted to hospital. Many patients who are at high risk of death are prescribed beta-blockers, but later choose to stop taking them because of symptoms that they perceive to be side-effects. Some patients' symptoms may genuinely be side-effects due to the beta-blocker tablets, but, in reality, many of the symptoms which may lead to people stopping beta-blockers are actually experienced at similar rates compared to placebo. The symptoms may be caused by heart failure itself, or the expectation that they will have a side effect when they take a tablet (the nocebo effect). There is a need to be able to identify the majority of patients who aren't actually having side-effects so that they can restart beta-blockers and not miss out on life-prolonging treatment. To answer this question reliably and with high precision requires a personalised approach with an 'N-of-1' study. This study will measure participants' symptoms in three scenarios: taking a beta-blocker tablet (bisoprolol 2.5mg) or a placebo tablet or no study medication in a randomised order. The primary aim of this study is to determine, for an individual, whether the adverse effects of beta-blockade in heart failure are genuine. Specifically, the objectives are: 1. To determine the proportion of a patient's symptoms that are due to taking beta-blocker tablets, and the proportion that are due to the expectation that the treatment will cause symptoms (the nocebo effect). 2. To determine whether, on average, symptoms are worse when taking beta-blocker compared to placebo tablets or no treatment. 3. To determine whether on average symptom intensity associated with beta-blockade decreases after receiving a report on how much of their symptoms are due to the beta-blocker. Throughout the protocol participants report daily the intensity of the symptom that previously led to their beta-blocker cessation via a smartphone app. Participants will report weekly their adherence, general heart failure symptoms and quality of life. In this way the investigators will discover, for an individual patient, the proportion of their symptom that is due to the beta-blocker tablet, and whether knowing their personalised results helps them to restart beta-blocker tablets. Read Less

Gender:

ALL

Ages:

18 years and above

Trial Updated:

06/17/2025

Locations: Imperial College London, London, Not set

Conditions: Side-Effect, Heart Failure

Register for Updates

Learn More ›

Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)

NCT05714085

Recruiting

This study aims to compare the efficacy of vericiguat versus placebo on change in n-terminal pro-brain natriuretic peptide (NTproBNP) from baseline to Week 16 of the Base Period. The primary hypothesis is that vericiguat is superior to placebo in reducing NT-proBNP at Week 16 of the Base Period.

Gender:

ALL

Ages:

Between 29 days and 17 years

Trial Updated:

06/11/2025

Locations: Loma Linda University Health System ( Site 0008), Loma Linda, California +92 locations

Loma Linda University Health System ( Site 0008), Loma Linda, California

The Regents of the University of California - Los Angeles (UCLA Pediatrics) ( Site 0002), Los Angeles, California

Children's Hospital Colorado ( Site 0012), Aurora, Colorado

Children's National Medical Center ( Site 0020), Washington, District of Columbia

Johns Hopkins All Children's Hospital ( Site 0029), Saint Petersburg, Florida

Children's Healthcare of Atlanta - Arthur M. Blank Hospital ( Site 0001), Atlanta, Georgia

C.S. Mott Children's Hospital ( Site 0033), Ann Arbor, Michigan

Washington University-Pediatric Cardiology/ St. Louis Children's Hospital ( Site 0006), Saint Louis, Missouri

The Children's Hospital at Montefiore ( Site 0030), Bronx, New York

Columbia University Medical Center-Pediatric Cardiology ( Site 0016), New York, New York

Cincinnati Children's Hospital Medical Center ( Site 0034), Cincinnati, Ohio

Cleveland Clinic-Cleveland Clinic Chidren's ( Site 0022), Cleveland, Ohio

Children's Hospital of Philadelphia (CHOP) ( Site 0004), Philadelphia, Pennsylvania

Children's Hospital of Pittsburgh ( Site 0010), Pittsburgh, Pennsylvania

Le Bonheur Children's Hospital ( Site 0007), Memphis, Tennessee

Children's Health-The Heart Center ( Site 0015), Dallas, Texas

Seattle Children's Hospital-Cardiology/Fetal Therapy ( Site 0019), Seattle, Washington

Centre Hospitalier Régional de la Citadelle ( Site 0302), Liège, Liege

UZ Gent ( Site 0301), Gent, Oost-Vlaanderen

UZ Leuven ( Site 0300), Leuven, Vlaams-Brabant

Instituto Dante Pazzanese de Cardiology ( Site 0402), São Paulo, Sao Paulo

Incor - Instituto do Coracao ( Site 0400), Sao Paulo, Not set

Stollery Children's Hospital ( Site 0501), Edmonton, Alberta

Centre intégré universitaire de santé et de services sociaux-Centre de recherche du CHUS ( Site 0502), Sherbrooke, Quebec

Clinica Somer ( Site 0607), Rionegro., Antioquia

Ciensalud Ips S A S ( Site 0608), Barranquilla, Atlantico

Fundación Cardioinfantil Instituto de Cardiología ( Site 0603), Bogotá, Distrito Capital De Bogota

Fundación Valle del Lili ( Site 0604), Cali, Valle Del Cauca

Clínica Imbanaco S.A.S ( Site 0602), Cali, Valle Del Cauca

Rigshospitalet-BørneUngeAfdelingen ( Site 0800), Copenhagen, Hovedstaden

Tampereen yliopistollinen sairaala-Pediatric Early Phase Trials Unit ( Site 0900), Tampere, Pirkanmaa

CHU Bordeaux Haut-Leveque ( Site 1000), Pessac, Aquitaine

CHU Lille - Institut Coeur Poumon ( Site 1005), Lille Cedex, Nord

Centre Hospitalier Universitaire de Nantes - Hôpital Femme-Enfant-Adolescent Chu De Nantes ( Site 1002), Nantes, Pays-de-la-Loire

Assistance Publique Hôpitaux de Marseille - Hôpital de la Timone ( Site 1003), Marseille, Provence-Alpes-Cote-d Azur

Hôpital Universitaire Necker Enfants Malades ( Site 1001), Paris, Not set

Assistance Publique - Hopitaux de Paris (AP-HP) - Hopital Robert Debre - Centre Hospitalo Universita ( Site 1004), Paris, Not set

Universitaetsklinikum Freiburg ( Site 1102), Freiburg, Baden-Wurttemberg

Universitaetsklinikum Heidelberg ( Site 1100), Heidelberg, Baden-Wurttemberg

Kinderklinik des Uni-Klinikums Erlangen ( Site 1104), Erlangen, Bayern

Medizinische Hochschule Hannover ( Site 1108), Hannover, Niedersachsen

Deutsches Herzzentrum Berlin ( Site 1101), Berlin, Not set

Gottsegen György Országos Kardiovaszkuláris Intézet-Gyermeksziv Kozpont ( Site 1300), Budapest, Not set

Children's Health Ireland (CHI) at Crumlin ( Site 1400), Dublin, Not set

IRCCS Istituto Giannina Gaslini ( Site 1603), Genova, Liguria

A.O.Universitaria Meyer ( Site 1600), Firenze, Toscana

Azienda Ospedale - Università Padova ( Site 1601), Padova, Veneto

Pusan National University Yangsan Hospital ( Site 2802), Pusan, Kyongsangnam-do

Seoul National University Hospital ( Site 2803), Seoul, Not set

Severance Hospital, Yonsei University Health System ( Site 2800), Seoul, Not set

Samsung Medical Center ( Site 2801), Seoul, Not set

Hospital Universiti Sains Malaysia ( Site 1703), Kota Bharu, Kelantan

University Malaya Medical Centre ( Site 1701), Lembah Pantai, Kuala Lumpur

Hospital Tunku Azizah-Paediatric ( Site 1700), Kuala Lumpur, Not set

Institut Jantung Negara ( Site 1705), Kuala Lumpur, Not set

Instituto Nacional de Pediatria ( Site 1803), Mexico City, Distrito Federal

Morales Vargas Centro de Investigacion ( Site 1810), León, Guanajuato

CINVEC Medica ( Site 1814), Guadalajara, Jalisco

Centro de Estudios de Investigacion Metabolicos y Cardiovasculares ( Site 1800), Ciudad Madero, Tamaulipas

Centro de Atención e Investigación Clínica ( Site 1813), Aguascalientes, Not set

INVECORDIS S.C. ( Site 1808), Hacienda De Las Palmas, Not set

Instituto Nacional de Cardiologia Ignacio Chavez ( Site 1804), Mexico, Not set

Erasmus Medisch Centrum ( Site 1900), Rotterdam, Zuid-Holland

University Medical Center Groningen ( Site 1901), Groningen, Not set

Universitair Medisch Centrum Utrecht ( Site 1902), Utrecht, Not set

Auckland City Hospital ( Site 2000), Auckland, Not set

Instituto Nacional Cardiovascular INCOR Carlos Peschiera Carrillo - EsSalud ( Site 2100), Jesús María, Lima

Uniwersyteckie Centrum Kliniczne-Klinika Kardiologii Dziecięcej i Wad Wrodzonych Serca ( Site 2302), Gdańsk, Pomorskie

Unidade Local de Saude Lisboa Ocidental - Hospital de Santa Cruz ( Site 2401), Lisbon, Lisboa

Unidade Local de Saude de Santa Maria - Hospital de Santa Maria ( Site 2402), Lisboa, Not set

Unidade Local de Saúde de São João ( Site 2403), Porto, Not set

National University Hospital-Paediatrics ( Site 2600), Singapore, South West

KK Women's and Children's Hospital ( Site 2601), Singapore, South West

TREAD Research ( Site 2700), Cape Town, Western Cape

Children's Heart Disease Research Unit ( Site 2704), Cape Town, Western Cape

Hospital Sant Joan de Déu-Pediatric cardiology ( Site 2902), Esplugues de Llobregat, Barcelona

Hospital Universitari Vall d'Hebron ( Site 2903), Barcelona, Cataluna

Hospital Materno-Infantil Teresa Herrera ( Site 2905), A Coruna, La Coruna

HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑON ( Site 2904), Madrid, Madrid, Comunidad De

Hospital Universitario La Paz ( Site 2912), Madrid, Madrid, Comunidad De

HOSPITAL UNIVERSITARIO VIRGEN DEL ROCIO ( Site 2907), Sevilla, Not set

Skånes Universitetssjukhus Lund ( Site 3000), Lund, Skane Lan

Astrid Lindgrens Barnsjukhus ( Site 3001), Stockholm, Stockholms Lan

Faculty of Medicine - Khon Kaen University ( Site 3202), Muang, Khon Kaen

Faculty of Medicine Siriraj Hospital ( Site 3200), Bangkok, Krung Thep Maha Nakhon

Maharaj Nakorn Chiang Mai Hospital-Department of Pediatrics ( Site 3201), Chiang Mai, Not set

Hacettepe Universite Hastaneleri ( Site 3304), Ankara, Not set

Baskent Universitesi Ankara Hastanesi ( Site 3301), Ankara, Not set

Ankara Bilkent Şehir Hastanesi. ( Site 3300), Ankara, Not set

Dr. Siyami Ersek Göğüs Kalp Ve Damar Cerrahisi Eğitim Ve Araştırma Hastanesi ( Site 3302), Istanbul, Not set

S.B.Ü. DR. BEHÇET UZ ÇOCUK HASTALIKLARI VE CERRAHİSİ EĞİTİM VE ARAŞTIRMA HASTANESİ ( Site 3303), Izmir, Not set

Great Ormond Street Hospital For Children NHS Foundation Trust ( Site 3401), London, London, City Of

Freeman Hospital ( Site 3400), Newcastle upon Tyne, Not set

Conditions: Heart Failure, Left Ventricular Systolic Dysfunction

Register for Updates

Learn More ›

The STOP-MED CTRCD Trial

NCT06183437

Recruiting

Cancer therapy-related cardiac dysfunction (CTRCD) is when the heart's ability to pump oxygenated blood to the body is compromised. It is a side effect of cancer therapy which can occur as commonly as in 1 in 5 patients. When this occurs, heart failure medications are started to protect the heart from progressing to heart failure. With early detection and treatment, heart function recovers to normal in \>80% of patients. Unfortunately, heart failure medications are associated with an undesirable... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

06/05/2025

Locations: Brigham and Women's Hospital, Boston, Massachusetts +9 locations

Conditions: Heart Failure, Cardiotoxicity, Cardiac Toxicity, Antineoplastics Toxicity, Cancer

Register for Updates

Learn More ›

Use of a Novel SUBCUTaneous Preparation of Furosemide to Facilitate Early Supported Discharge of Patients With Heart Failure

NCT05419115

Recruiting

To investigate whether an early supported discharge strategy for patients admitted to hospital because of HF, using a pH neutral subcutaneous (SC) furosemide formulation (SQINFurosemide) at home (delivered by non-CE marked SQINInfusor), compared to a usual care strategy with intravenous (IV) furosemide in hospital, results in an increased number of days spent alive and out of hospital (DAOH) at 30 days.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

04/11/2025

Locations: Stoke Mandeville Hospital, Aylesbury, England +21 locations

Conditions: Heart Failure

Register for Updates

Learn More ›

Study to Collect High-Resolution ECG Data and Patient Insights on Heart Failure Care

NCT06809686

Recruiting

The purpose of this study is to establish an electrocardiogram (ECG) data library to facilitate future studies on heart disease. Additionally, the study will be used to monitor changes in the patient's standard of care throughout the study period and gather patient perspectives on routine diagnostic procedures and disease monitoring and feedback on the design of heart failure trials.

Gender:

ALL

Ages:

Between 45 years and 80 years

Trial Updated:

03/18/2025

Locations: Richmond Pharmacology, London, Not set +1 locations

Conditions: Heart Failure

Register for Updates

Learn More ›

EMPOWER-1: A Multi-site Clinical Cohort Research Study to Reduce Health Inequality

NCT03987633

Recruiting

Health inequality and genetic disparity are a significant issue in the United Kingdom (UK). This study focuses on diseases that are associated with significant morbidity and mortality in the UK, and specifically examines the extent and basis of treatment failure in different patient populations. The vast majority of drug registration clinical trials have under-representation of ethnic minority populations. In addition, the wider Caucasian populations have reasonably different clinical characte... Read More

Gender:

ALL

Ages:

6 years and above

Trial Updated:

03/05/2025

Locations: Future Genetics, The Science Centre, Wolverhampton Science Park, Wolverhampton, West Midlands

Conditions: Atrial Fibrillation, Coronary Heart Disease, Cardiovascular Diseases, Heart Failure, Hypertension, Peripheral Arterial Disease, Stroke, Ischemic, Asthma, Chronic Obstructive Pulmonary Disease, Obesity, Cancer, Chronic Kidney Diseases, Diabetes Mellitus, Dementia, Depression, Epilepsy, Mental Health Disorder, Rheumatoid Arthritis, Blood Pressure, Breast Cancer Risk, Prostate Cancer, Lung Cancers

Register for Updates

Learn More ›

Heart Failure in Patients With Diabetes: Cells, Crosstalk and Consequences

NCT06774014

Recruiting

This will be an observational study to explore differences in pathophysiology between groups of people with and without heart failure (HF) (reduced and preserved ejection fraction) and with and without diabetes mellitus (DM) with a particular focus on cross-talk (fat, muscle, vascular tissue and the heart). The investigators will invite 600 people to partcipate (100 with HFrEF+DM, 100 with HFpEF+DM, 100 with HFpEF-DM, 100 with HFrEF-DM, 100 with DM, 100 without either HR or DM). Special heart sc... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

02/27/2025

Locations: Leeds Teaching Hospitals NHS Trust, Leeds, West Yorkshire

Conditions: Diabetes Mellitus Type 2, Heart Failure, HFrEF - Heart Failure With Reduced Ejection Fraction, HFpEF - Heart Failure With Preserved Ejection Fraction

Register for Updates

Learn More ›

The Effect of Obesity and Weight Loss in Heart Failure With Reduced Ejection Fraction.

NCT05942287

Recruiting

This study looks at the effects of weight loss in people who have heart failure with reduced ejection fraction (HFpEF) and are overweight or obese. The main questions it aims to answer are whether weight loss in this group of people improves: * The heart's shape and how well it pumps blood * The person's quality of life and how much they can exercise Participants will attend 2 study visits, separated by 3-6 months. The intervention period takes place in between the 2 study visits. Each study... Read More

Gender:

ALL

Ages:

Between 18 years and 85 years

Trial Updated:

02/21/2025

Locations: Jersey General Hospital, Jersey, Not set +1 locations

Conditions: Heart Failure, Heart Failure With Reduced Ejection Fraction, Obesity, Overweight

Register for Updates

Learn More ›

RCT of Implantable Defibrillators in Patients with Non Ischemic Cardiomyopathy, Scar and Severe Systolic Heart Failure

NCT05568069

Recruiting

BRITISH is a UK multicentre trial of patients who have been diagnosed with heart failure due to Non-Ischemic Cardiomyopathy (NICM, or heart failure that is not caused by blocked heart arteries. Participants will be randomised into two groups. Half the participants will receive an Implantable Cardioverter-Defibrillator (ICD) and the other half will not. The aim of the study will be to compare all-cause mortality (death from any cause) between these two groups at 36 months, and longer-term to 10 y... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

01/23/2025

Locations: Wycombe Hospital, High Wycombe, Buckinghamshire +46 locations

Wycombe Hospital, High Wycombe, Buckinghamshire

Derriford Hospital, Plymouth, Devon

Royal Bournemouth Hospital, Bournemouth, Dorset

Durham & Darlington NHS Foundation Trust, Darlington, Durham

Royal Sussex County Hospital, Brighton, East Sussex

Essex Cardiothoracic Centre, Basildon, Essex

James Paget University Hospitals NHS FT, Gorleston-on-Sea, Great Yarmouth

Portsmouth Hospitals University NHS Trust, Portsmouth, Hampshire

Southampton Clinical Trials Unit, Southampton, Hampshire

University Hospital Southampton NHS Foundation Trust, Southampton, Hampshire

Kent & Canterbury Hospital, Canterbury, Kent

Maidstone Hospital, Maidstone & Tunbridge Wells NHS Trust, Maidstone, Kent

Blackpool Victoria Hospiatal, Blackpool, Lancashire

Liverpool Heart & Chest, Liverpool, Lancashire

Glenfield Hospital, Leicester, Leicestershire

St George's Hospital, Tooting, London

Newcastle Freeman Hospital, Newcastle, Newcastle upon Tyne

The James Cook University Hospital, Middlesbrough, North Yorkshire

Wansbeck General Hospital, Ashington, Northumbria

Scarborough Hospital, Scarborough, Nortrh Yorkshire

Nottingham City Hospital, Nottingham, Nottinghamshire

The John Radcliffe Hospital, Oxford, Oxfordshire

Aberdeen Royal Infirmary, Aberdeen, Scotland

Royal Infirmary of Edinburgh, Edinburgh, Scotland

Musgrove Park Hospital, Taunton, Somerset

Northern General Hospital, Sheffield, South Yorkshire

University Hospital of North Tees, Hardwick, Stockton-on-Tees

Frimley Park Hospital, Camberley, Surrey

Surrey & Sussex Healthcare NHS Trust, Redhill, Surrey

University Hospital of Wales, Cardiff, Wales

University Hospital Coventry, Coventry, Warwickshire

New Cross Hospital, Wolverhampton, West Midlands

St Richards Hospital, Chichester, West Sussex

Leeds General Infirmary, Leeds, West Yorkshire

Pinderfields Hospital, Wakefield, West Yorkshire

Worcestershire Royal Hospital, Worcester, Worcestershire

Wythenshaw Hospital, Manchester, Wythenshaw

Castle Hill Hospital, Hull, Yorkshire

Royal Devon & Exeter Hospital, Exeter, Not set

St Bartholomew's Hospital, London, Not set

Royal Free Hospital, London, Not set

Guy's Hospital, London, Not set

King's College Hospital, London, Not set

Royal Brompton Hospital, London, Not set

Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, Not set

Fairfield General Hospital, Northern Care Alliance NHS FT, Manchester, Not set

Morriston Hospital, Swansea, Not set

Conditions: Heart Failure

Register for Updates

Learn More ›

Lifestyle Behaviours of Women Newly Diagnosed With Heart Failure

NCT05416879

Recruiting

Heart Failure occurs when the heart's ability to pump blood is reduced. Heart failure can lead to symptoms of breathlessness, fatigue and ankle swelling, and result in health complications including damage to other organs (e.g. kidneys), reduced function and quality of life. Although the symptoms of heart failure are similar for men and women, there are sex differences. Lifestyle behaviours such as physical activity are important modifiable risk factor for heart failure. Women continue to be und... Read More

Gender:

FEMALE

Ages:

18 years and above

Trial Updated:

12/09/2024

Locations: Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, Not set

Conditions: Heart Failure

Register for Updates

Learn More ›

Heart Failure Clinical Trials in United Kingdom

Match to Clinical Trials